Nuclear medicine is rapidly evolving with new molecular imaging targets and advanced computational tools that promise to enhance diagnostic precision and personalized therapy. Recent years have seen a surge in novel PET and SPECT tracers, such as those targeting prostate-specific membrane antigen (PSMA) in prostate cancer, fibroblast activation protein (FAP) in tumor stroma, and tau protein in neurodegenerative disease. These tracers enable more specific visualization of disease processes compared to traditional agents, fitting into a broader shift toward precision imaging in oncology and neurology. In parallel, artificial intelligence (AI) and machine learning techniques are being integrated into tracer development and image analysis. AI-driven methods can accelerate radiopharmaceutical discovery, optimize pharmacokinetic properties, and assist in interpreting complex imaging datasets. This editorial provides an expanded overview of emerging imaging targets and techniques, including theranostic applications that pair diagnosis with radionuclide therapy, and examines how AI is augmenting nuclear medicine. We discuss the implications of these advancements within the field's historical trajectory and address the regulatory, manufacturing, and clinical challenges that must be navigated. Innovations in molecular targeting and AI are poised to transform nuclear medicine practice, enabling more personalized diagnostics and radiotheranostic strategies in the era of precision healthcare.

This narrative review outlines the current applications and considerations of artificial intelligence (AI) for diagnosis, management, and prognosis in rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA). Advances in AI, mainly in machine learning and deep learning, have significantly influenced medical research and clinical practice over the past decades by offering precisions in data understanding and treatment approaches. AI applications have enhanced risk prediction models, early diagnosis, and better management in RA. Predictive models have guided treatment decisions such as-response to methotrexate and biologics-while wearable devices and electronic health records (EHR) improve disease activity monitoring. In addition, AI applications are reported as promising for the early identification of extra-articular involvements, prediction, detection, and assessment of comorbidities. In axSpA, AI-driven models using imaging techniques such as sacroiliac radiography, magnetic resonance imaging, and computed tomography have increased diagnostic accuracy, especially for early inflammatory changes. Predictive algorithms help stratify and predict disease outcomes, while clinical decision support systems integrate clinical and imaging data for optimized management. For PsA, AI has also allowed for early detection among psoriasis patients using genetic markers, immune profiling, and EHR-based natural language processing systems. Overall, AI models may predict diagnosis, disease severity, treatment response, and comorbidities to improve care in patients with RA, axSpA, and PsA. As a rapidly developing and improving area, AI has the potential to change our current perspective of medical practice by offering better diagnostic evaluation and treatments and improved patient follow-up. Multimodal AI, focusing on collaboration, reliability, transparency, and patient-centered innovation, looks like the future of medical practice. However, data quality, model interpretability, and ethical considerations must be addressed to ensure reliable and equitable applications in clinical practice.

Radiology has usually been the field of medicine that has been at the forefront of technological advances, often being the first to wholeheartedly embrace them. Whether it's from digitization to cloud side architecture, radiology has led the way for adopting the latest advances. With the advent of large language models (LLMs), especially with the unprecedented explosion of freely available ChatGPT, time is ripe for radiology and radiologists to find novel ways to use the technology to improve their workflow. Towards this, we believe these LLMs have a key role in the radiology reading room not only to expedite processes, simplify mundane and archaic tasks, but also to increase the radiologist's and radiologist trainee's knowledge base at a far faster pace. In this article, we discuss some of the ways we believe ChatGPT, and the likes can be harnessed in the reading room.

Diagnosis and treatment of endometrial diseases are crucial for women's health. Over the past decade, ultrasound has emerged as a non-invasive, safe, and cost-effective imaging tool, significantly contributing to endometrial disease diagnosis and generating extensive datasets. The introduction of artificial intelligence has enabled the application of machine learning and deep learning to extract valuable information from these datasets, enhancing ultrasound diagnostic capabilities. This paper reviews the progress of artificial intelligence in ultrasound image analysis for endometrial diseases, focusing on applications in diagnosis, decision support, and prognosis analysis. We also summarize current research challenges and propose potential solutions and future directions to advance ultrasound artificial intelligence technology in endometrial disease diagnosis, ultimately improving women's health through digital tools.